Physician profile
Mark R Weiser
NPI 1487621249
$11,525.82
in general payments reported to CMS, 2019-2025
42 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $689 · 2021: $2,313 · 2022: $2,440 · 2023: $1,313 · 2024: $1,849 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,709.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,213.83 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,660.79 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,147.34 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $793.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $784.21 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $670.74 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $491.32 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Ironwood Pharmaceuticals, INC | $420.26 | 2020-2025 | Linzess |
| Sanofi-Aventis U.S. LLC | $286.42 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $276.24 | 2021-2025 | Eliquis |
| Mylan Specialty L.P. | $224.71 | 2019-2024 | Yupelri |
| Abbott Laboratories | $219.23 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $192.26 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company Ltd. | $188.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.98 | 2022-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $182.13 | 2022 | |
| Allergan, INC. | $167.34 | 2019-2021 | |
| Astellas Pharma US INC | $166.71 | 2019-2025 | Veozah |
| Amgen INC. | $140.32 | 2020-2025 | Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $130.73 | 2021-2022 | |
| Exact Sciences Corporation | $106.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $85.67 | 2023-2025 | General - Pain Management |
| Xeris Pharmaceuticals, INC. | $82.73 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.34 | 2024-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $79.51 | 2021 | |
| Eisai INC. | $77.01 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $68.86 | 2022 | |
| Genentech USA, INC. | $60.96 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $57.22 | 2021-2022 | |
| Medtronic, INC. | $48.71 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $37.99 | 2022-2023 | Quviviq |
| Ardelyx, INC. | $37.14 | 2025 | Ibsrela |
| Hologic Sales and Service, LLC | $21.66 | 2025 | Thinprep 2000 Processor, Aptima |
| Viatris Specialty LLC | $19.98 | 2025 | Yupelri |
| Shield Therapeutics INC | $18.65 | 2024 | |
| Tactile Systems Technology INC | $16.53 | 2025 | Nimbl, Flexitouch Plus |
| Collegium Pharmaceutical, INC. | $16.42 | 2022 | |
| Nevro Corp. | $15.63 | 2022 | |
| Lundbeck LLC | $15.08 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $12.39 | 2021 | |
| Corium, LLC | $12.34 | 2023 | Adlarity |
| Teva Pharmaceuticals USA, INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.